Expression analysis of lncRNA Morrbid and NeST lncRNA in patients with Coronavirus disease 2019 and their clinical signs
This study demonstrates that the immune-related long non-coding RNAs Morrbid and NeST are significantly upregulated in the peripheral blood mononuclear cells of COVID-19 patients compared to healthy controls, suggesting their potential as biomarkers for the host immune response to SARS-CoV-2 infection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a complex fortress, constantly patrolled by an immune system designed to recognize and neutralize invaders. When a virus like SARS-CoV-2 enters the scene, this defense network springs into action, deploying a variety of cells and chemical signals to fight the infection. For decades, scientists focused primarily on the proteins and genes that directly code for these defenses. However, a quieter layer of genetic regulation has recently come into focus: long non-coding RNAs. These are strands of genetic material that do not build proteins but instead act as managers, turning other genes on or off to fine-tune the immune response. Understanding how these managers behave during a viral outbreak could reveal why some people fight off an infection easily while others suffer severe illness, potentially offering new ways to track the disease's progress.
In a study conducted by researchers at Fasa University of Medical Sciences in Iran, the focus turned to two specific genetic managers known as Morrbid and NeST. These molecules are known to influence how immune cells survive and how they produce powerful antiviral signals. The research team set out to see if the levels of these two molecules changed in people infected with COVID-19 compared to healthy individuals. To do this, they recruited fifty adults who had a confirmed diagnosis of the virus and fifty healthy adults who served as a control group. The researchers drew blood from each participant and isolated a specific type of white blood cell called a peripheral blood mononuclear cell, which acts as a central hub for immune activity. They then extracted the genetic material from these cells to measure how much of the Morrbid and NeST molecules were present.
The results showed a clear difference between the two groups. In the patients with COVID-19, the amount of Morrbid was significantly higher than in the healthy controls. Similarly, the levels of NeST were also elevated in the infected group. The researchers found that the median amount of Morrbid in patients was 34.693 compared to 15.590 in the control group, while NeST levels were 252.172 in patients versus 92.272 in controls. These findings suggest that when the body encounters the SARS-CoV-2 virus, it ramps up the production of these specific genetic managers, likely as part of the effort to coordinate the immune defense. The study indicates that these molecules are not just passive bystanders but are actively involved in the body's reaction to the virus.
The team also looked to see if these changes were linked to specific characteristics of the patients, such as their age, gender, blood type, or whether they had other health conditions like heart disease. They found no such connection. The rise in Morrbid and NeST appeared to be a general response to the infection itself, rather than a reaction tied to a person's demographic background or pre-existing health issues. Furthermore, the researchers examined whether the levels of these molecules differed between patients who had symptoms like fever or cough and those who did not. The data showed no significant difference in expression based on the presence or absence of these common symptoms, suggesting that the genetic response was consistent across the patient group regardless of how they felt.
While the study provides strong evidence that these molecules are upregulated during infection, the authors are careful to note that this is a preliminary step. The research did not include experiments to prove exactly how these molecules are helping or harming the patient, nor did it test whether they could be used as a diagnostic tool in a hospital setting. The variation in expression levels between individuals was also considerable, meaning that the numbers were not identical for every patient. The researchers conclude that while Morrbid and NeST appear to be promising candidates for understanding the immune response to COVID-19, larger studies and further functional tests are needed to confirm their exact role and potential value in clinical practice. For now, the work establishes a clear link between the presence of the virus and the activity of these specific genetic regulators in the blood.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.